Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications

Menno van Woerkom, Hans Piepenbrink, Brian Godman, Joost de Metz, Stephen Campbell, Marion Bennie, Marietta Eimers, Lars L Gustafsson

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Multiple reforms have recently been introduced in The Netherlands to improve prescribing efficiency. These include preference pricing policies for multiple sourced products, guidelines, and quality and efficiency targets, as well as regular pharmacotherapy meetings.
Assess the influence of these multiple measures on prescribing efficiency.
Retrospective observational study of all reimbursed prescriptions for proton pump inhibitors and statins between 2000 and 2010 using the Genees-en hulpmiddelen Informatie Project (Health Insurance) database. Utilization measured in defined daily doses. Narrative review of reforms.
Reimbursed expenditure for the proton pump inhibitors fell by 58% in 2010 versus 2000 despite a threefold increase in utilization, helped by increasing utilization of generic omeprazole at only 2% of the prepatent loss price in 2010. Similarly, reimbursed expenditure for the statins fell by 14% in 2010 versus 2000 despite a 3.8-fold increase in utilization. Again, this was helped by increasing utilization of generic simvastatin at only 2% of the prepatent loss originator price.
Multiple supply and demand measures, including the preference pricing policy, appear to have appreciably enhanced proton pump inhibitor and statin prescribing efficiency, providing examples to other countries.

LanguageEnglish
Pages527-538
Number of pages12
JournalJournal of Comparative Effectiveness Research
Volume1
Issue number6
DOIs
Publication statusPublished - Nov 2012

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Proton Pump Inhibitors
Netherlands
Health Expenditures
Costs and Cost Analysis
Simvastatin
Omeprazole
Health Insurance
Observational Studies
Prescriptions
Retrospective Studies
Databases
Guidelines
Drug Therapy

Keywords

  • prescribing efficiency
  • proton pump inhibitors
  • statins
  • netherlands
  • influence and implications
  • genees-en hulpmiddelen informatie project

Cite this

Woerkom, Menno van ; Piepenbrink, Hans ; Godman, Brian ; Metz, Joost de ; Campbell, Stephen ; Bennie, Marion ; Eimers, Marietta ; Gustafsson, Lars L. / Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands : influence and future implications. In: Journal of Comparative Effectiveness Research. 2012 ; Vol. 1, No. 6. pp. 527-538.
@article{024d90260ea84c34955882d264334d72,
title = "Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications",
abstract = "Multiple reforms have recently been introduced in The Netherlands to improve prescribing efficiency. These include preference pricing policies for multiple sourced products, guidelines, and quality and efficiency targets, as well as regular pharmacotherapy meetings. Assess the influence of these multiple measures on prescribing efficiency. Retrospective observational study of all reimbursed prescriptions for proton pump inhibitors and statins between 2000 and 2010 using the Genees-en hulpmiddelen Informatie Project (Health Insurance) database. Utilization measured in defined daily doses. Narrative review of reforms. Reimbursed expenditure for the proton pump inhibitors fell by 58{\%} in 2010 versus 2000 despite a threefold increase in utilization, helped by increasing utilization of generic omeprazole at only 2{\%} of the prepatent loss price in 2010. Similarly, reimbursed expenditure for the statins fell by 14{\%} in 2010 versus 2000 despite a 3.8-fold increase in utilization. Again, this was helped by increasing utilization of generic simvastatin at only 2{\%} of the prepatent loss originator price. Multiple supply and demand measures, including the preference pricing policy, appear to have appreciably enhanced proton pump inhibitor and statin prescribing efficiency, providing examples to other countries.",
keywords = "prescribing efficiency, proton pump inhibitors, statins, netherlands, influence and implications, genees-en hulpmiddelen informatie project",
author = "Woerkom, {Menno van} and Hans Piepenbrink and Brian Godman and Metz, {Joost de} and Stephen Campbell and Marion Bennie and Marietta Eimers and Gustafsson, {Lars L}",
year = "2012",
month = "11",
doi = "10.2217/cer.12.52",
language = "English",
volume = "1",
pages = "527--538",
journal = "Journal of Comparative Effectiveness Research",
issn = "2042-6313",
number = "6",

}

Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands : influence and future implications. / Woerkom, Menno van; Piepenbrink, Hans; Godman, Brian; Metz, Joost de; Campbell, Stephen; Bennie, Marion; Eimers, Marietta; Gustafsson, Lars L.

In: Journal of Comparative Effectiveness Research, Vol. 1, No. 6, 11.2012, p. 527-538.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands

T2 - Journal of Comparative Effectiveness Research

AU - Woerkom, Menno van

AU - Piepenbrink, Hans

AU - Godman, Brian

AU - Metz, Joost de

AU - Campbell, Stephen

AU - Bennie, Marion

AU - Eimers, Marietta

AU - Gustafsson, Lars L

PY - 2012/11

Y1 - 2012/11

N2 - Multiple reforms have recently been introduced in The Netherlands to improve prescribing efficiency. These include preference pricing policies for multiple sourced products, guidelines, and quality and efficiency targets, as well as regular pharmacotherapy meetings. Assess the influence of these multiple measures on prescribing efficiency. Retrospective observational study of all reimbursed prescriptions for proton pump inhibitors and statins between 2000 and 2010 using the Genees-en hulpmiddelen Informatie Project (Health Insurance) database. Utilization measured in defined daily doses. Narrative review of reforms. Reimbursed expenditure for the proton pump inhibitors fell by 58% in 2010 versus 2000 despite a threefold increase in utilization, helped by increasing utilization of generic omeprazole at only 2% of the prepatent loss price in 2010. Similarly, reimbursed expenditure for the statins fell by 14% in 2010 versus 2000 despite a 3.8-fold increase in utilization. Again, this was helped by increasing utilization of generic simvastatin at only 2% of the prepatent loss originator price. Multiple supply and demand measures, including the preference pricing policy, appear to have appreciably enhanced proton pump inhibitor and statin prescribing efficiency, providing examples to other countries.

AB - Multiple reforms have recently been introduced in The Netherlands to improve prescribing efficiency. These include preference pricing policies for multiple sourced products, guidelines, and quality and efficiency targets, as well as regular pharmacotherapy meetings. Assess the influence of these multiple measures on prescribing efficiency. Retrospective observational study of all reimbursed prescriptions for proton pump inhibitors and statins between 2000 and 2010 using the Genees-en hulpmiddelen Informatie Project (Health Insurance) database. Utilization measured in defined daily doses. Narrative review of reforms. Reimbursed expenditure for the proton pump inhibitors fell by 58% in 2010 versus 2000 despite a threefold increase in utilization, helped by increasing utilization of generic omeprazole at only 2% of the prepatent loss price in 2010. Similarly, reimbursed expenditure for the statins fell by 14% in 2010 versus 2000 despite a 3.8-fold increase in utilization. Again, this was helped by increasing utilization of generic simvastatin at only 2% of the prepatent loss originator price. Multiple supply and demand measures, including the preference pricing policy, appear to have appreciably enhanced proton pump inhibitor and statin prescribing efficiency, providing examples to other countries.

KW - prescribing efficiency

KW - proton pump inhibitors

KW - statins

KW - netherlands

KW - influence and implications

KW - genees-en hulpmiddelen informatie project

U2 - 10.2217/cer.12.52

DO - 10.2217/cer.12.52

M3 - Article

VL - 1

SP - 527

EP - 538

JO - Journal of Comparative Effectiveness Research

JF - Journal of Comparative Effectiveness Research

SN - 2042-6313

IS - 6

ER -